Atacand and Conjunctivitis aggravated - a phase IV clinical study of FDA data

Summary:

Conjunctivitis aggravated is reported as a side effect among people who take Atacand (candesartan cilexetil), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Atenolol, and have Primary myelofibrosis.

The phase IV clinical study analyzes which people have Conjunctivitis aggravated when taking Atacand. It is created by eHealthMe based on reports of 21,732 people who have side effects when taking Atacand from the FDA, and is updated regularly.

What is Atacand?

Atacand has active ingredients of candesartan cilexetil. It is often used in high blood pressure. eHealthMe is studying from 22,473 Atacand users. Check the latest studies of Atacand.

What is Conjunctivitis aggravated?

Conjunctivitis aggravated (infection of conjunctiva) is found to be associated with 1,044 drugs and 366 conditions by eHealthMe. Check the latest studies of Conjunctivitis aggravated.

On Jul, 13, 2026

21,732 people reported to have side effects when taking Atacand.
Among them, 35 people (0.16%) have Conjunctivitis aggravated.

Could Atacand cause Conjunctivitis aggravated?

Among these 35 people:

How long have people been on Atacand when they have Conjunctivitis aggravated? *

What is the gender of people who have Conjunctivitis aggravated when taking Atacand? *

female: 64.52 %
male: 35.48 %

What is the age of people who have Conjunctivitis aggravated when taking Atacand? *

What are other drugs people take besides Atacand? *

What are other side effects people have besides Conjunctivitis aggravated? *

Nausea (feeling of having an urge to vomit): 14 people, 40.00%
Fatigue (feeling of tiredness): 13 people, 37.14%
Weakness: 11 people, 31.43%
Acute Kidney Failure: 10 people, 28.57%
Weight Decreased: 9 people, 25.71%
Urinary Tract Infection: 9 people, 25.71%
Emotional Disorder: 8 people, 22.86%
Pain: 8 people, 22.86%
Nausea And Vomiting: 8 people, 22.86%
Fainting (loss of consciousness and postural tone): 8 people, 22.86%

What are the existing conditions these people have? *

Breast Cancer Metastatic: 4 people, 11.43%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 4 people, 11.43%
Primary Myelofibrosis (primary disorder of the bone marrow): 4 people, 11.43%
Osteoporosis (bones weak and more likely to break): 3 people, 8.57%
Acidosis (build-up of carbon dioxide in the blood): 2 people, 5.71%
Gastric Ulcer (stomach ulcer): 2 people, 5.71%
High Blood Cholesterol: 2 people, 5.71%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 2 people, 5.71%
Renal Cell Carcinoma (a kidney cancer): 2 people, 5.71%
Lymphoedema (localized fluid retention and tissue swelling): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Atacand and have Conjunctivitis aggravated?

- Check whether Conjunctivitis aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Atacand:

Atacand (22,473 reports)

Browse all side effects of Atacand:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Conjunctivitis aggravated:

Conjunctivitis aggravated (1,044 drugs)

Browse all the conditions that are associated with Conjunctivitis aggravated:

Conjunctivitis aggravated (366 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on candesartan cilexetil (the active ingredients of Atacand) and Atacand (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.